Davis Polk & Wardwell advised Texas Instruments Incorporated on the offering, and Simpson Thacher & Bartlett advised the underwriters. Texas Instruments Incorporated (TI) (Nasdaq: TXN) announced its SEC-registered offering...
You must be a Standard 1 Year member to access this content.
Davis Polk & Wardwell advised Ultra Clean Holdings, Inc. on the transaction. Ultra Clean Holdings, Inc. (UCT) announced its acquisition of HIS Innovations Group. UCT paid $50...
You must be a Standard 1 Year member to access this content.
Davis Polk & Wardwell advised Upgrade, Inc. on the transaction. Upgrade, Inc. announced the acquisition of Uplift, Inc., the leading provider of Buy Now Pay Later (BNPL)...
You must be a Standard 1 Year member to access this content.
Davis Polk advised the underwriter on the transaction. Mirion Technologies announced the $52.9 million offering of 7,000,000 shares of Class A common stock of Mirion Technologies,...
You must be a Standard 1 Year member to access this content.
Davis Polk advised Texas Instruments Incorporated, while Simpson Thacher & Bartlett acted for the underwriters in connection with the offering. Texas Instruments Incorporated (NASDAQ:TXN) announced the...
You must be a Standard 1 Year member to access this content.
Gibson, Dunn & Crutcher advised Intel, while Davis Polk & Wardwell advised the underwriters on the offering. Intel Corporation executed the offering consisting of $1.25 billion aggregate principal...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Allakos, while Davis Polk advised the underwriter, Cowen, in the offering. Allakos Inc. announced it may issue and sell shares of...
You must be a Standard 1 Year member to access this content.
Latham & Watkins LLP represented Sight Sciences, Inc. in the offering, while Davis Polk advised the representatives of the several underwriters. Sight Sciences, Inc. executed its initial public...
You must be a Standard 1 Year member to access this content.
Davis Polk advised the underwriters in the offering. Theravance Biopharma, Inc. executed its $100.5 million public offering of ordinary shares. Theravance Biopharma’s ordinary shares are listed on the Nasdaq...
You must be a Standard 1 Year member to access this content.
